• COVID-19 & Nebulized Therapies

    Attention Midwest Allergy and Asthma patients:   Recent data indicates that COVID-19 can persist in droplets in the air for 1 to 2 hours after nebulized therapies.  We are recommending that patients minimize use of nebulized therapies if possible.  If nebulized therapies are necessary, we recommend administering in a location that minimizes exposure to other

    Read more →
  • Intranasal and Inhaled Corticosteroids and the COVID-19 Pandemic

    ACAAI Statement on Intranasal and Inhaled Corticosteroids and the COVID-19 Pandemic As spring allergy season sets in, allergy and asthma sufferers may be concerned that continuing their normal use of inhaled and intranasal corticosteroids may not be advisable during the pandemic. However, it is more important than ever for these patients to keep their symptoms

    Read more →
  • FDA Alerts Patients of EpiPen auto-injector errors

    FDA alerts patients and health care professionals of EpiPen auto-injector errors related to device malfunctions and user administration   Today the US Food and Drug Administration (FDA) is alerting patients, caregivers and health care professionals that EpiPen 0.3 mg and EpiPen Jr 0.15 mg auto-injectors, and the authorized generic versions, may potentially have delayed injection

    Read more →
  • Attention Patients: COVID-19

    Attention Patients! With the many unknowns due to the outbreak of the Coronavirus, the physicians of Midwest Allergy and Asthma Clinic would like to encourage our patients to consider not only receiving care in the clinic, but over the phone as well. The Coronavirus is a respiratory disease and as an allergy and asthma clinic

    Read more →